In chronic kidney disease, the pivotal FLOW trial demonstrated that semaglutide 1 mg reduced the risk of major kidney events by 24% in patients with type 2 diabetes and CKD, resulting in a dedicated indication in this population
The GIP / GLP-1 dual-agonist is increasingly winning share as Eli Lillys previous generation GLP-1 agonist Trulicity (20% share) declines
#PharmaInnovation #Endocrinology #CardiovascularHealth #GLP1 #Rybelsus #Semaglutide #MedicalAffairs #LifeSciences To view or add a comment, sign in Suzetrigine (Journavx) The First New Non-Opioid Analgesic in 20+ Years Historic Milestone: FDA Approves Suzetrigine, a Non-Opioid Alternative for Acute Pain In January 2025, the U.S
In addition, an oxidative stress model was established by treating SRA01/04 lens epithelial cells with H 2 O 2 , and cell viability, proliferation, apoptosis, and hub gene expression were assessed using CCK8, EdU, flow cytometry, and qPCR
Therefore, SOD and catalase could be inhibited by these free radicals
GH promotes lipolysis the breakdown of stored fat for energy
